Board summary
Key figures
59,116
Registered population
60.0% aged 18–64
19.7%
Aged 65+
ICB 19.0% · England 17.9%
9.4%
Ethnic minority (non-White)
3.9% Asian · England 9.6%
43.9%
In IMD quintile 1
ICB 31.9% · England 21.0%
~25,830
Core20 residents (est.)
Resident basis; registered basis ~27,370 · see page 3
10,544
Hypertension register
+6.24% in 3 yrs · England +5.60%
736
SMI register
8.8% of Liverpool (LAD)'s
2,024
COPD register
Reviews +14.50% in 3 yrs
Forecast to 2030
12,402
Hypertension patients, 2030
+1,858 on today
83.5%
QRISK ≥20% on statins, 2030
+5.92pp over 3 yrs
5.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma reviews trail despite high prescribing.
Annual reviews fell -2.1% over 3 years to 58.9% (England 65.7%), leaving about 1,600 of 3,839 patients unreviewed while youth prescribing reaches 2,639 per.
Pre-school boosters lag the 95.0% target.
At age 5, 4-in-1 coverage is 76.0% (19 pp below the 95.0% target) and MMR2 is 78.4% (8.7 pp below MMR1 at 87.1%).
Lipid therapy and blood pressure exceed England.
QRISK ≥ 20% lipid therapy rose +9.3% over 3 years to 69.9% (England 63.6%), alongside 71.6% hypertension control (England 70.3%).
Population, age and ethnicity
Older adults comprise 19.7% of list, exceeding Liverpool's 15.6% alongside 883 care beds
IGPC PCN serves 59,116 registered patients. Patients aged 65+ account for 19.7% of the list (11,645 patients), compared with Liverpool (LAD) at 15.6%, NHS Cheshire and Merseyside Integrated Care Board at 19.0%, and England at 17.9%. Children aged 0-17 represent 20.3% (Liverpool (LAD) 19.8%; ICB 19.2%; England 19.6%), while 60.0% are aged 18-64 (Liverpool (LAD) 64.5%; ICB 61.9%; England 62.7%). Census resident data shows 90.6% White ethnicity (Liverpool (LAD) 84.0%; ICB 93.0%; England 81.1%), leaving a 9.4% non-White resident share; resident Census figures do not match registered patient ethnicity.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Liverpool (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Liverpool LA) | 3,035 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.7% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Liverpool LA) | 1,652 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Liverpool LA) | 27.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 43.9% PCN-wide but practice shares span 81.0 pp
Across IGPC PCN, 43.9% of registered patients live in Core20 areas, compared with 54.9% in Liverpool (LAD), 31.9% in the ICB, and 21.0% in England. The weighted practice share is 46.3%, a 2.39 percentage points discrepancy against the PCN rate. Deprivation is sharply uneven: practice concentration spans 81.0 pp, with Rock Court Surgery at 81.0% and Rocky Lane Medical Centre at 0.0%. By volume, Old Swan Health Centre (6,979 patients) and Belle Vale Health Centre (6,579) carry the largest cohorts. Targeting must balance practice concentration against patient volume so large.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
736
SMI register
1.24% recorded prevalence
382
Learning disability register
0.65% recorded prevalence
22
Care homes, 883 beds
In the PCN catchment
10.3%
Provide unpaid care
Liverpool (LAD), Census 2021
The PCN records 736 patients on the severe mental illness register (1.2% versus Liverpool (LAD) 1.4%, ICB 1.1%, England 1.0%) and 382 on the learning disability register (0.7% versus 0.6% across Liverpool (LAD), ICB and England), alongside 883 beds across 22 catchment care homes. Crude recorded prevalence and care home bed capacity do not establish resident occupancy or which registered patients use these facilities.
Severe mental illness: physical health checks
Across 736 patients on the severe mental illness register (1.2%, England 1.0%), annual blood pressure checks reached 83.6% (England 83.4%) and BMI checks 82.9% (England 82.1%). Psychosis alcohol recording reached 86.4% (England 81.8%); broader physical checks were uncaptured.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
10,544
Hypertension register
+6.24%
Register growth, 3 yrs
Liverpool (LAD) +2.01% · England +5.60%
+5.07pp
BP control, under 80
≤140/90 · +3.26pp aged 80+
+1,858
More patients by 2030
Forecast 12,402 (20.12%)
Hypertension case-finding and control
Recorded hypertension prevalence is 17.8% (10,544 patients), above Liverpool (LAD) at 14.0%, the ICB at 16.8% and England at 15.2%. Hypertensive patients treated to target reach 71.6%, exceeding Liverpool (LAD) at 69.8%, the ICB at 69.1% and England at 70.3%. However, annual heart failure reviews including functional capacity assessment fell 1.6% over three years (England +8.7%) to 73.8%, trailing England at 78.5% and the ICB at 76.4%, though above Liverpool (LAD) at 73.3%, across 752 registered patients (1.3% prevalence). While blood pressure control exceeds benchmarks, heart failure annual reviews trail England and ICB levels, indicating that prioritizing heart failure recall could address patients missing annual reviews.
Lipids and statins
In primary prevention, 69.9% of patients with QRISK ≥ 20% receive lipid-lowering therapy, above Liverpool (LAD) at 65.6%, the ICB at 63.2% and England at 63.6%, rising +9.3% over three years (England +6.2%). With coverage exceeding all benchmarks, prioritizing routine annual recall will help sustain high primary prevention therapy across the PCN.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 127,178 | £1.90 | £1.71 | £1.86 | £241,638 |
| Cardiovascular (all), 2025 | 171,593 | £4.40 | £4.37 | £3.33 | £755,009 |
In 2026, the PCN prescribed 127,178 lipid-modifying items at £1.90 per item (spend £241,638), above Liverpool (LAD) at £1.82, the ICB at £1.71 and England at £1.86, spending £5,087 more than at England's unit cost. Prescribing unit costs exceed comparators, so examining product mix across practices could clarify what drives this spend difference.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−2.15%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.34%
Asthma prevalence, PCN 3-yr % change
The PCN records 3,839 asthma patients (6.9% prevalence, England 6.6%) and 2,024 COPD patients (3.4%, England 1.9%). While COPD reviews reached 78.8% (England 76.4%), asthma reviews fell 2.1% over three years (England +4.4%) to 58.9% (England 65.7%; Liverpool (LAD) 64.3%), leaving about 1,600 patients unreviewed. Paediatric asthma prescribing reached 2,639 items per 1,000 aged 5-19 (England 1,488), while second-hand smoking recording lagged at 72.3% (England 78.8%). This pattern may reflect recall or maintenance gaps to verify locally.
Cancer register and children's immunisation
The cancer register records 2,723 patients (4.6% prevalence, England 3.8%). In Q1 2025/26, childhood immunisations trail national standards across 171 children at age 5. MMR2 coverage is 78.4% (below the 95.0% target by 16.6 pp; England 82.8%), trailing MMR1 (87.1%) by 8.7 pp. The 4-in-1 pre-school booster reaches 76.0% (below the 95.0% target by 19 pp; England 80.9%), indicating drop-off before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of cancers with a known stage (7,482 of 13,490) were diagnosed at stage 1 or 2 (England 55.3%), 19.5 pp below the 75.0% national ambition by 2028, requiring about 2,640 extra early diagnoses annually. Staged cancers represented 72.8% of 18,522 registered tumours, with early diagnosis up 2.6 pp since 2013 ICB-wide. At PCN level, cervical screening coverage is 71.9% (England 66.8%), though Dovecot Health Centre achieves 64.3%, Old Swan Health Centre achieves 64.5%, and Calvary Health Centre achieves 66.4%. Prioritising screening recall in lower-coverage practices could help identify pre-cancerous changes earlier.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Liverpool University Hospitals NHS Foundation Trust, 62-day referral-to-treatment performance trailed the 85.0% standard by 11.7 pp, while NHS Cheshire and Merseyside Integrated Care Board was 8.8 pp below standard. On the 28-day faster diagnosis standard, the trust met the 75.0% threshold (0.5 pp above standard), while the ICB was 2.2 pp above. For the 31-day combined treatment standard, the trust was 5.5 pp below the 96.0% standard, compared with the ICB at 0.3 pp below. Provider waits on 62-day and 31-day pathways may delay treatment for referred patients, underscoring the importance of robust secondary-care tracking.
| Pathways within standard (%) | Liverpool | Mersey and West Lancashire | Wirral | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.47 | 72.39 | 74.71 | 77.25 | 79.32 |
| 31-day treatment (96%) | 90.51 | 95.46 | 92.53 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 73.26 | 77.96 | 77.65 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Liverpool | Mersey and West Lancashire | Wirral | England |
|---|---|---|---|---|
| MRI | 6.42 | 14.04 | 1.54 | 21.40 |
| CT | 0.71 | 13.08 | 1.55 | 9.92 |
| Echocardiography | 12.55 | 34.88 | 5.07 | 28.48 |
| Colonoscopy | 33.14 | 18.04 | 32.81 | 30.83 |
| Gastroscopy | 44.99 | 18.17 | 17.73 | 29.02 |
| All 15 DM01 tests | 11.50 | 21.17 | 5.02 | 23.14 |
| Community services activity | Liverpool residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 127,380 | 541,280 |
| Referrals | 15,675 | 97,150 |
| Patients with a contact | 24,970 | 146,240 |
Community services (residents of Liverpool), Jun 2026 (provisional). For Liverpool (LAD) residents, older adults aged 65+ accounted for 65.4% of community service contacts (83,300 of 127,380 contacts) in provisional Jun 2026 data. Community health services support older adults across the borough, though contacts reflect wider local authority activity rather than PCN-level oncology care.
Practice variation and patient experience
Practice variation and patient experience
Clinical QOF achievement is consistently high, reaching 96.4% to 100.0% across practices against England's 97.1%. However, the vaccination and immunisation domain lags across all eight practices at 15.6% to 21.6% (England 55.2%), spanning 6.0 pp. Personalised care adjustments across all domains average 4.5% to 9.6% against England's 10.0%.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Calvary | 94 | 51.5 | 86.0% | 63.9% | 96.0% |
| Dovecot | 107 | 80.8 | 74.9% | 72.9% | 92.6% |
| Rock Court Surgery | 105 | 81.0 | 50.9% | 70.6% | 87.6% |
| Rocky Lane | 88 | 0.0 | 64.6% | 68.0% | 78.3% |
| Old Swan | 91 | 77.7 | 63.8% | 75.0% | 73.1% |
| West Derby | 110 | 19.0 | 32.5% | 64.5% | 70.8% |
| Belle Vale | 98 | 78.0 | 53.0% | 79.6% | 68.0% |
| Oak Vale | 103 | 12.5 | 35.3% | 64.6% | 63.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Three-year register growth and chronic reviews trailed England despite strong screening gains
Over three years, heart failure reviews fell 1.6% (England +8.7%), with current reviews at 73.8% (England 78.5%), and asthma reviews fell 2.1% (England +4.4%). Three-year register growth trailed England for learning disability (+0.03% versus +5.4%), COPD (+0.1% versus +2.6%) and stroke (+0.6% versus +2.3%). Conversely, breast screening rose 24.2% (England +8.4%) to 72.1% (England 69.9%), dementia registers grew 16.9% (England +6.0%), and mental health alcohol recording rose 13.4 pp (England +5.4 pp) to 86.4% (England 81.8%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
Learning disability register
COPD register
Stroke register
Breast screening (53-70)
COPD reviews
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Liverpool (LAD) | Asset | PCN | Liverpool (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 22 (883 beds) | n/a | Schools (catchment) | 112 | n/a |
| Children's centres | 7 | 26 | Places of worship | 55 | 240 |
| Libraries | 4 | 17 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 30 | 91 | Primary academies | 4 | 20 |
| Special schools | 3 | 8 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and prescribing recall
Asthma reviews sit at 58.9% (England 65.7%; Liverpool (LAD) 64.3%) after falling 2.1% over 2023 to 2025 (England +4.4%), leaving about 1,600 of 3,839 registered patients unreviewed. For discussion: practices could run a standardised recall template combining annual review, inhaler check and second-hand smoke recording, offering after-school slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Heart failure review and capacity audit
Heart failure reviews with functional capacity assessment sit at 73.8% (England 78.5%; ICB 76.4%; Liverpool (LAD) 73.3%) across 752 patients (1.3% prevalence), falling 1.6% over 2023 to 2025 (England +8.7%). For discussion: practices could audit the 752-patient register for overdue reviews and embed functional capacity prompts into multi-morbidity templates. Moderate effort to run.
Option 3
Pre-school booster and MMR2 catch-up recall
In Q1 2025/26 (171 children aged 5), MMR2 is 78.4% (below the 95.0% target by 16.6 pp; England 82.8%), 8.7 pp below MMR1 (87.1%); 4-in-1 is 76.0% (below 95.0% by 19 pp). For discussion: practices could audit age-5 cohorts and proactively recall families missing MMR2 or 4-in-1 booster doses. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult service planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Two-track Core20 resource allocation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Sustain severe mental illness checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Heart failure review audit (p5) | Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) | — | PCN |
| Pre-school immunisation call and recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma review and prescribing recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Heart failure review and capacity audit (p12) | Heart failure register · Heart Failure: QOF prevalence · Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) | — | PCN |
| Option 3 · Pre-school booster and MMR2 catch-up recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
